Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity

NCT07073417 is registered in ClinicalTrials.gov with Hangzhou Sciwind Biosciences Co., Ltd. as lead sponsor.

NCT NCT07073417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07073417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 28, 2025
Completion date
August 23, 2027
Enrollment
163 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, weight management